TD Asset Management
AVIR icon

TD Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

TD Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,853
Closed -$367K – 1465
2022
Q1 		$367K Hold
50,853
– – ﹤0.01% 1376
2021
Q4 		$455K Sell
50,853
-41,614
-45% -$648K ﹤0.01% 1395
2021
Q3 		$3.24M Hold
92,467
– – ﹤0.01% 945
2021
Q2 		$2.31M Buy
92,467
+67,482
+270% +$2.03M ﹤0.01% 1054
2021
Q1 		$1.54M Buy
24,985
+4,298
+21% +$290K ﹤0.01% 1167
2020
Q4 		$864K Buy
+20,687
New +$667K ﹤0.01% 1213

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TD Asset Management's AVIR Position: Q2 2022 in Review

TD Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 50,853 shares — an estimated $367K sold.

TD Asset Management first reported a position in AVIR in Q4 2020 and held it in 6 quarters. The position peaked at $3.24M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • TD Asset Management reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • TD Asset Management sold 50,853 Atea Pharmaceuticals shares in Q2 2022, an estimated $367K.
  • TD Asset Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • TD Asset Management's Atea Pharmaceuticals position peaked at $3.24M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on TD Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.